International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Myasthenic Crisis:Clinical Features, Mortality, Comp, & Risk Factors for Prolonged Intubation
Neurol 48:1253-1254, Thomas,C.E.,et al, 1997
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
Management of Stroke in Neonates and Children
Stroke 50:e51-e96, Ferriero, D.M.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Fat Embolism Syndrome Secondary to Bone Marrow Necrosis in Patients with Hemoglobinopathies
SMJ 109:549-553, Gangaraju, R.,et al, 2016
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Bone Marrow Necrosis and Fat Embolism Syndrome in Sickle Cell Disease: Increased Susceptibility of Patients with Non-SS genotypes and a Possible Association with Human Parvovirus B19 Infection
Blood Rev 28:23-30, Tsitsikas, D.A.,et al, 2014
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Moyamoya Disease and Moyamoya Syndrome
NEJM 360:1226-1237, Scott,R.M. &Smith,E.R., 2009
Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Stroke 37:577-617, Sacco,R.L.,et al, 2006
A Diagnostic Approach to Multiple Simultaneous Intracerebral Hemorrhages
Neurocrit Care 4:267-271, Finelli,P.F., 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Apoplexy in Pituitary Macroadenoma: Eight Patients Presenting in 12 Months
Medicine 84:188-196, Imboden,E.,e tal, 2005
Adrenoleukodystrophy
JAMA 294:3131-3134, Moser,H.W.,et al, 2005
Therapy for Nerve Agent Poisoning
Arch Neurol 61:649-652, Newmark,J., 2004
Aromatic L-Amino Acid Decarboxylase Deficiency
Neurol 62:1058-1065, Pons,R.,et al, 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Paraneoplastic Syndromes Involving the Nervous System
NEJM 349:1543-1554, Darnell,R.B. &Posner,J.B., 2003
Sickle Cell Disease: The Neurological Complications
Ann Neurol 51:543-552, Prengler,M.,et al, 2002
Stroke Prevention and Treatment in Sickle Cell Disease
Arch Neurol 58:565-568, Adams,R.J., 2001
Clinicopath Conf,Systemic Sclerosis with Scleroderma Renal Crisis
NEJM 345:596-605, Case 26-2001, 2001
Thrombotic Thrombocytopenic Purpura:Brain CT and MRI Findings in 12 Patients
Neurol 52:1285-1288, Bakshi,R.,et al, 1999
Paraneoplastic Syndromes
Arch Neurol 56:405-408, Dalmau,J.O.&Posner,J.B., 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Neurology and the Blood:Haematological Abnormalities in Ischaemic Stroke
JNNP 64:150-159, Markus,H.S.&Hambley,H., 1998
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998
Ion Channels and Neurological Disease:DNA Based Diagnosis is Now Possible,and Ion Channels May be Important in Common Paroxysmal Disorders
JNNP 65:427-431, Hanna,M.G.,et al, 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
X Linked Adrenoleukodystrophy:Clinical Presentation, Diagnosis, and Therapy
JNNP 63:4-14, vanGeel,B.M.,et al, 1997
Calcium Channels in Neurological Disease
Ann Neurol 42:275-282, Greenberg,D.A., 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
MDMA (Ecstasy) and the Rave:A Review
Pediatrics 100:705-708, Schwartz,R.H.&Miller,N.S., 1997
Bilirubin Metabolism and Kernicterus
Adv Pediatr 44:173-229, Gourley,G.R., 1997
Basal Ganglia and Thalamic Infarction in Children
Arch Neurol 53:1252-1256, Brower,M.C.,et al, 1996
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995